Descriptive combination

COMBINATION PROFILE

GHK-Cu + KPV

Sources checked · October 16, 2026

Published for review · Scientific, medical, translation and citation review pending. Reported uses are not authorized indications. Frequency reflects mentions in supplied sources, not sales or global clinical prevalence.

Components

Community claim

Repair, skin or inflammation claims inferred from individual ingredients.

Community and market provenance

Community mention, not clinical evidence

    • Source: pdf08 · Page 4

    Evidence of the exact combination

    No controlled clinical validation of this exact marketed combination was established in this review. Ingredient evidence is not combination evidence.

    Component links are not combination evidence. A commercial name’s composition may vary.

    Uncertainty and risks

    No validated clinical interaction profile or synergy established; Cartalax identity/evidence requires further review where present.

    Observed in supplier/community material; prevalence not quantified.

    No dosing or mixing instructions are provided.

    Source issues and references

    References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.

    1. R02

      FDA: KPV evaluation, July 2026

    2. R06

      FDA: current bulk-substance safety-risk page

    3. R14

      Dalmasso et al.: PepT1-mediated KPV uptake, 2008

    A community-based bilingual scientific education initiative for healthcare professionals and the general public across the Americas.Currently self-funded; no current sponsors. Formal governance and legal documentation pending.info@peptideamericas.org · Planned contact address — not active yet; please do not send messages.